no credit card required  No credit card. No commitment.
 5000 plus G2 reviews  5000+ G2 reviews
Company logo

Editas Medicine

Editas Medicine


Editas Medicine's financial review

Editas Medicine's Revenue (Yearly)

78.1M

Employees

320

Total Funding

473.0M

Last Funding Round

215.6M

nasdaq

EDIT

Market cap

462.2M


Editas Medicine information

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We're a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture...
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We're a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors', and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we've already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

Editas Medicine industries

Genome editing
In vivo editing
Engineered cell medicines
Ocular medicines

Editas Medicine's financial review

Editas Medicine's Revenue (Yearly)

78.1M

Employees

320

Total Funding

473.0M

Last Funding Round

215.6M

nasdaq

EDIT

Market cap

462.2M

Technologies

Email Providers
Domain Name Services
Email Providers
Analytics and Tracking

Notable Alumni

Aaron Wilson
Associate Director, Head of Lab Automation & Screening
Alltrna
Caleigh Griffin
Program Coordinator - Corporate Learning
Harvard Medical School
Chia-Yu Wang
Engineer II, Cell Process Development
Clade Therapeutics
Daphne Farrington
Vice President Clinical Development
OnCusp Therapeutics
Emily Doll
Associate Director, Accounting Operations
GentiBio

Job Postings

Cambridge, United States
Cambridge, United States
Cambridge, United States

Employees

QC Analyst II
Associate Scientist I
Associate Scientist I
Human Genetics and Genomics Co-op

Prospect on LinkedIn

Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download ExtensionRepresents linkedin prospector
Browse Apollo's Directories

Why our clients choose Apollo

“Apollo completely changed the game for us. It allowed us to identify relevant targets that are ready to scale and reach out to them at the exact right time.”
Image of Erik Straub

Erik Straub

Head of Product, Kickfurther

“Using Apollo.io, we've solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects.”
Image of Michael Transon

Michael Transon

CEO, Victorious

Apollo gives you all the company insights you need

Free to get started, easy to add your whole sales team, commit to monthly or annual plans. We make it easy to get started.